Medline to buy Ecolab’s surgical products for nearly $1B
The medical products supplier will gain Ecolab’s sterile drapes and fluid temperature management systems.
Medline to buy Ecolab’s surgical products for nearly $1B Read More »
Uncategorized
CVS slashes 2024 outlook — again — as Medicare seniors drive spending
Runaway inpatient spending in particular caused CVS’ insurance costs to snowball after returning “to patterns we have not seen since the start of the pandemic,” its CFO said.
CVS slashes 2024 outlook — again — as Medicare seniors drive spending Read More »
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
Cocrystal Pharma, Inc. announces completion of enrollment of 78 subjects who were infected with influenza A in a randomized, double-blind, placebo-controlled Phase 2a human challenge clinical study evaluating the safety, tolerability, antiviral and clinical measurements of its novel, broad-spectrum, oral PB2 inhibitor CC-42344.
Neurocrine Wins FDA Approval for ‘Sprinkle’ Formulation of Ingrezza for Huntington’s Disease
Neurocrine Biosciences on Tuesday won the FDA’s approval for a sprinkle capsule formulation of Ingrezza, providing a more convenient route of treatment for Huntington’s disease patients with trouble swallowing.
Tenet raises full-year revenue guidance on $2.2B in Q1 profit
CEO Saum Sutaria says the health system is a “new company” following nine hospital sales in the first quarter.
Tenet raises full-year revenue guidance on $2.2B in Q1 profit Read More »
Pfizer Beats Q1 Forecast Despite 20% Revenue Drop, Cuts Four Pipeline Programs
Despite being hit with a 20% sales decline due to a plunge in demand for its COVID-19 products, Pfizer on Wednesday reported $14.88 billion in revenue in the first quarter of 2024 exceeding analyst expectations.
Pfizer Beats Q1 Forecast Despite 20% Revenue Drop, Cuts Four Pipeline Programs Read More »
Atlanta’s Biotech Scene Prepares for New Heights
The Atlanta area is receiving more physical real estate options to foster its burgeoning biotech industry.
Atlanta’s Biotech Scene Prepares for New Heights Read More »
The IRA, BMS’ Big Cuts, First WHIM Approval
J&J and BMS’ challenges to Medicare drug price negotiations shut down in federal court less than a week after BMS announced it was laying off more than 2,000 employees.
Drug Companies, VCs Rethink R&D Strategies as IRA Stands Strong in Court
This week’s legal losses by J&J and BMS reinforce the notion that Medicare drug price negotiation is here to stay, and investors continue to favor biologics over small molecules.
Drug Companies, VCs Rethink R&D Strategies as IRA Stands Strong in Court Read More »
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
Altamira Therapeutics Ltd. today announced that it has filed a provisional patent application with the United States Patent Office (USPTO) which covers nanoparticles comprising the Company’s OligoPhore™ platform and siRNA targeting the p65 protein, a component of the NF-κB transcription factor.